DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bortezomib
Bortezomib
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib In
VELCADE® (Bortezomib) for Injection
Combining Milatuzumab with Bortezomib, Doxorubicin, Or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines Rhona Stein,1Mitchell R
Antitumor Effects of Bortezomib (PS-341) on Primary Effusion Lymphomas
Bortezomib Plus Docetaxel in Advanced Non-Small Cell Lung Cancer and Other Solid Tumors: a Phase I California Cancer Consortium Trial
Thesis Biochemistry By
Velcade, INN-Bortezomib
Generated by Bortezomib Immune Mechanism of the Antitumor Effects
Prescribing Information | VELCADE® (Bortezomib)
Recent Advances in the Management of Hormone Refractory Prostate Cancer
ORIGINAL ARTICLE Sequence-Dependent Synergy Of
Cancer Nanobiotechnolgy
WO 2016/179306 Al 10 November 2016 (10.11.2016) P O P C T
NCCP Chemotherapy Regimen
Omacetaxine May Have a Role in Chronic Myeloid Leukaemia Eradication Through Downregulation of Mcl-1 and Induction of Apoptosis in Stem/Progenitor Cells
Bortezomib, Paclitaxel, and Carboplatin As a First-Line
Cyclophosphamide / Bortezomib / Dexamethasone (Vcd)
VCD) Versus Bortezomib, Doxorubicin and Dexamethasone (Pad) in Newly Diagnosed Myeloma
Top View
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
A Phase I/II Study of Bortezomib in Combination with Paclitaxel
Non Commercial Use Only
Pfizer Bortezomib Powder for Injection
Bc Cancer Chemotherapy Preparation and Stability
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Bortezomib Given? If You Have Any Questions About Your Treatment, Speak to Your Medical Team
Subcutaneous Administration of Anticancer Agents
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
Bortezomib Added to Daunorubicin and Cytarabine During Induction
Open Full Page
How to Order Chemotherapy at Shands at the University of Florida - Inpatient
A Phase 2 Study of Bortezomib Combined with Either Idarubicin
Pdf 972.38 K
Protein Synthesis Inhibitor Omacetaxine Is Effective Against Hepatocellular Carcinoma
Therapeutic Role of Arsenic Trioxide in Cancer Protection Archana Chaudhary and Rizwanul Haque*
Bortezomib, Cyclophosphamide & Dexamethasone Multiple Myeloma
Velcade, INN-Bortezomib
High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome Inhibitors
Drug Interactions Between the Proteasome Inhibitor Bortezomib
Bortezomib in the Rapid Reduction of High Sustained Antibody Titers in Disorders Treated with Therapeutic Protein: Lessons Learned from Pompe Disease
A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
Cell-Type-Specific Sensitivity of Bortezomib in the Methotrexate
Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-21)
VELCADE® (Bortezomib) for Injection
The Proteasome Inhibitor Bortezomib Acts Differently in Combination With
Arsenic Trioxide
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for Thetreatment of Relapsed Or Refractory Multiple Myeloma James R
Bortezomib (Velcade®) (“Bore-TEZ-Oh-Mib”)
Bortezomib Interactions with Chemotherapy Agents in Acute Leukemia in Vitro
Revlimid, INN-Lenalidomide
Guidelines for the Use of Anti-Emetics with Chemotherapy
Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Combination in Waldenstrom Macroglobulinemia
Original Article Effects and Mechanisms of Bortezomib Combined with Arsenic Trioxide on Multiple Myeloma
Phase I/II Study of Bortezomib Plus Docetaxel in Patients With
Current Management Approaches of Chronic Myeloid Leukemia
Characteristics of Non-Randomized Studies Using Comparisons with External Controls Submitted for Regulatory Approval in the Us and Europe: a Systematic Review
TVCN Blank Document
Ascorbic Acid Inhibits Antitumor Activity of Bortezomib in Vivo
Safety and Efficacy of Vorinostat, Bortezomib, Doxorubicin And
In Relapsed and Refractory Multiple Myeloma
Reference ID: 3733596
Bortezomib for Prevention of Acute Graft-Versus-Host Disease: a Conclusion Reached Paul J
Effects of the Proteasome Inhibitor Bortezomib Alone and in Combination with Chemotherapeutic Agents in Gastric Cancer Cell Lines
Chemotherapy Protocol MULTIPLE MYELOMA PAD (IV)
Hazardous Drug List
MYBORPRE Protocol
Open Full Page
Comparison of Bortezomib, Cyclophosphamide, And
Hypoxia Promotes Synergy Between Mitomycin C and Bortezomib
Tyrosine Kinase-Targeting Drugs-Associated Heart Failure